Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001667:Binding, Competitive; D001943:Breast Neoplasms; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000737:chemistry*; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D004355:Drug Stability; D020847:Estrogen Receptor Modulators / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D005557:Formaldehyde / Q000737:chemistry*; D006801:Humans; D006868:Hydrolysis; D008958:Models, Molecular; D011092:Polyethylene Glycols / Q000737:chemistry; D011960:Receptors, Estrogen / Q000187:drug effects / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000737:chemistry
D000970:Antineoplastic Agents; D020847:Estrogen Receptor Modulators; D011960:Receptors, Estrogen; D013629:Tamoxifen; C016601:afimoxifene; D005557:Formaldehyde; C028914:triethylene glycol; D011092:Polyethylene Glycols; D004317:Doxorubicin